Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
- Robert T. Naismith
- , Jerry S. Wolinsky
- , Annette Wundes
- , Christopher LaGanke
- , Douglas L. Arnold
- , Dragana Obradovic
- , Mark S. Freedman
- , Mark Gudesblatt
- , Tjalf Ziemssen
- , Boris Kandinov
- , Ilda Bidollari
- , Maria Lopez-Bresnahan
- , Narinder Nangia
- , David Rezendes
- , Lili Yang
- , Hailu Chen
- , Shifang Liu
- , Jerome Hanna
- , Catherine Miller
- , Richard Leigh-Pemberton
Research output: Contribution to journal › Article › peer-review
56
Link opens in a new tab
Scopus
citations